<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628394</url>
  </required_header>
  <id_info>
    <org_study_id>0803-476</org_study_id>
    <secondary_id>1R34MH075863-01A2</secondary_id>
    <nct_id>NCT00628394</nct_id>
  </id_info>
  <brief_title>Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation</brief_title>
  <official_title>Cognitive Treatments in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done because people with schizophrenia often have problems with&#xD;
      thinking including learning, remembering, paying attention, and problem solving. During this&#xD;
      study, we will test if cognitive remediation (computer games made to improve thinking), used&#xD;
      along with a drug called atomoxetine, may help the problems in thinking as well as some of&#xD;
      the symptoms of schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persons with schizophrenia in a stable and residual antipsychotic- treated clinical condition&#xD;
      for at least 8 weeks will be recruited from several public mental health treatment settings&#xD;
      into the UTSW Schizophrenia Research Clinic. Each volunteer will receive information about&#xD;
      the protocol and its risks and benefits. If they give their informed consent after a full&#xD;
      opportunity to learn about the details of the study, they will be allowed to proceed. All&#xD;
      recruits will have been treated with optimal dosing of any 2nd generation antipsychotic drug&#xD;
      (APD-2) and will have been clinically stable with respect to psychotic symptoms for at least&#xD;
      6 weeks prior to randomization, and on a stable dose of the medication for at least 2 weeks.&#xD;
      All eligible volunteers will receive a routine medical assessment and psychiatric diagnostic&#xD;
      work-up including the SCID and a consensus diagnosis by two experienced clinicians based on&#xD;
      all available data, prior to the randomization. Just prior to randomization, the following&#xD;
      sets of assessments will be performed: (1) Medical: Physical Examination, Clinical&#xD;
      Chemistries, EKG, urinalysis, weight, and vital signs; (2) Symptomatic: general psychiatric&#xD;
      symptom assessment, including the scores on the PANSS, Psychosis Change Scale, and CGI; (3)&#xD;
      Cognitive: standard neuropsychometric test battery and surrogate psychosocial tests; all of&#xD;
      the assessment batteries will be repeated at the end of the 12-week treatment period, and&#xD;
      repeated again at the end of the three month follow-up period (at 6 months from study start).&#xD;
      Clinical symptom scales, weight, and vital signs will be repeated at weeks 4, 8, 12, 16 , and&#xD;
      24 during the study.&#xD;
&#xD;
      The schizophrenia volunteers will be randomized into four treatment groups: (1) atomoxetine&#xD;
      plus cognitive remediation; (2) atomoxetine plus remediation control; (3) placebo plus&#xD;
      cognitive remediation; and (4) placebo plus remediation control. Atomoxetine or matching&#xD;
      placebo will be administered at a dose of 40mg bid (80mg/day) or the placebo equivalent. The&#xD;
      remediation sequence will last for 60 minutes and will be administered three times weekly;&#xD;
      the remediation control will be administered on the same schedule and for the same duration.&#xD;
      Because the volunteers attend the clinic so regularly, we will have an opportunity to track&#xD;
      their progress, monitor medication adherence, and optimize study participation.&#xD;
&#xD;
      Then, each volunteer will be followed up while taking their blinded study medications, but&#xD;
      without any more remediation/control sessions, for the next 3 months. Psychiatric rating&#xD;
      scales will be completed the following times, relative to the blinded randomization:&#xD;
      baseline, 1, 2, 3, 4, 5, 6 months, whereas the neuropsychological battery will be completed&#xD;
      at baseline and at 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological Measures for MATRICS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gordon Continuous Performance Test - Distractibility Version The test is designed assess a person's executive functioning by testing their ability to maintain their focus over a period of time. They are intended to respond to a series of targets or inhibit their responses to a variety of foils. They are mainly assessed for their omissions and commissions. The omission and commission errors assess the person's ability to screen out extraneous stimuli while responding correctly and inhibiting incorrect responding. This means lower scores are better. The scale is 0-126.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Birchwood Social Function Scale (SFS) This scale is given to determine a person's ability to function independently and in social settings without difficulty. It assesses a variety of settings with independent subscales (whose scores vary in range) but in which the higher score is always better. These subscales (Withdrawal/Social Engagement; Interpersonal Communication; Independence-Performance; Independence-Competence; Recreation; Prosocial; and, Employment/Occupation) are combined and developed into a mean score. These scores range from 0-32.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Cognition in Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Atomox/CR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomox/Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given the drug Atomoxetine and Remediation Control training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/CR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given a Placebo and Cognitive Remediation training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given Placebo and Remediation Control training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>40mg 2po qam</description>
    <arm_group_label>Atomox/CR</arm_group_label>
    <arm_group_label>Atomox/Control</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40mg 2po qam</description>
    <arm_group_label>Placebo/CR</arm_group_label>
    <arm_group_label>Placebo/Control</arm_group_label>
    <other_name>Cornstarch capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis of schizophrenia or schizoaffective disorder.&#xD;
&#xD;
          -  Males and females.&#xD;
&#xD;
          -  Ages 18-60 years old.&#xD;
&#xD;
          -  All races and ethnicities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an organic brain disease.&#xD;
&#xD;
          -  Diagnosis of DSM-IV alcohol or substance abuse within the last month or DSM-IV alcohol&#xD;
             or substance dependence within the last 3 months.&#xD;
&#xD;
          -  Meet criteria for primary negative symptoms, established by clinical judgment.&#xD;
&#xD;
          -  Current or past history of clozapine treatment for antipsychotic non-response.&#xD;
&#xD;
          -  Patients hospitalized in a psychiatric hospital within the previous 30 days.&#xD;
&#xD;
          -  Patients with an unstable medical condition, as determined by the Investigator&#xD;
&#xD;
          -  Colorblindness&#xD;
&#xD;
          -  Concurrent treatment with electroconvulsive therapy or psychotherapy.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Must be able to read, speak, and understand English.&#xD;
&#xD;
               -  We do not have the resources necessary to properly study non-English speaking&#xD;
                  patients in this study. The computer software used for cognitive remediation and&#xD;
                  some clinical assessments are only available in English. The need to provide such&#xD;
                  resources in foreign languages would be prohibitive to the successful completion&#xD;
                  of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A Tamminga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <results_first_submitted>October 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Carol A. Tamminga</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>Atomoxetine</keyword>
  <keyword>Strattera</keyword>
  <keyword>cognitive remediation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Some participants were never randomized due to Screening labs, illicit substances (repeatedly - exclusion), transportation issues, or simply being lost to follow-up. Lost to f/u were contacted 3 times and sent a letter in order to bring them back into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomox/CR</title>
          <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="P2">
          <title>Atomox/Control</title>
          <description>Patients are given the drug Atomoxetine and Remediation Control training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="P3">
          <title>Placebo/CR</title>
          <description>Patients are given a Placebo and Cognitive Remediation training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
        <group group_id="P4">
          <title>Placebo/Control</title>
          <description>Patients are given Placebo and Remediation Control training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atomox/CR</title>
          <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="B2">
          <title>Atomox/Control</title>
          <description>Patients are given the drug Atomoxetine and Remediation Control training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="B3">
          <title>Placebo/CR</title>
          <description>Patients are given a Placebo and Cognitive Remediation training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
        <group group_id="B4">
          <title>Placebo/Control</title>
          <description>Patients are given Placebo and Remediation Control training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neuropsychological Measures for MATRICS</title>
        <description>Gordon Continuous Performance Test - Distractibility Version The test is designed assess a person's executive functioning by testing their ability to maintain their focus over a period of time. They are intended to respond to a series of targets or inhibit their responses to a variety of foils. They are mainly assessed for their omissions and commissions. The omission and commission errors assess the person's ability to screen out extraneous stimuli while responding correctly and inhibiting incorrect responding. This means lower scores are better. The scale is 0-126.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomox/CR</title>
            <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.&#xD;
Atomoxetine: 40mg 2po qam</description>
          </group>
          <group group_id="O2">
            <title>Atomox/Control</title>
            <description>Patients are given the drug Atomoxetine and Remediation Control training.&#xD;
Atomoxetine: 40mg 2po qam</description>
          </group>
          <group group_id="O3">
            <title>Placebo/CR</title>
            <description>Patients are given a Placebo and Cognitive Remediation training.&#xD;
Placebo: 40mg 2po qam</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Control</title>
            <description>Patients are given Placebo and Remediation Control training.&#xD;
Placebo: 40mg 2po qam</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Measures for MATRICS</title>
          <description>Gordon Continuous Performance Test - Distractibility Version The test is designed assess a person's executive functioning by testing their ability to maintain their focus over a period of time. They are intended to respond to a series of targets or inhibit their responses to a variety of foils. They are mainly assessed for their omissions and commissions. The omission and commission errors assess the person's ability to screen out extraneous stimuli while responding correctly and inhibiting incorrect responding. This means lower scores are better. The scale is 0-126.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.82" spread="1.71"/>
                    <measurement group_id="O2" value="18.03" spread="1.77"/>
                    <measurement group_id="O3" value="25.43" spread="1.64"/>
                    <measurement group_id="O4" value="11.64" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcomes</title>
        <description>Birchwood Social Function Scale (SFS) This scale is given to determine a person's ability to function independently and in social settings without difficulty. It assesses a variety of settings with independent subscales (whose scores vary in range) but in which the higher score is always better. These subscales (Withdrawal/Social Engagement; Interpersonal Communication; Independence-Performance; Independence-Competence; Recreation; Prosocial; and, Employment/Occupation) are combined and developed into a mean score. These scores range from 0-32.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomox/CR</title>
            <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.&#xD;
Atomoxetine: 40mg 2po qam</description>
          </group>
          <group group_id="O2">
            <title>Atomox/Control</title>
            <description>Patients are given the drug Atomoxetine and Remediation Control training.&#xD;
Atomoxetine: 40mg 2po qam</description>
          </group>
          <group group_id="O3">
            <title>Placebo/CR</title>
            <description>Patients are given a Placebo and Cognitive Remediation training.&#xD;
Placebo: 40mg 2po qam</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Control</title>
            <description>Patients are given Placebo and Remediation Control training.&#xD;
Placebo: 40mg 2po qam</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcomes</title>
          <description>Birchwood Social Function Scale (SFS) This scale is given to determine a person's ability to function independently and in social settings without difficulty. It assesses a variety of settings with independent subscales (whose scores vary in range) but in which the higher score is always better. These subscales (Withdrawal/Social Engagement; Interpersonal Communication; Independence-Performance; Independence-Competence; Recreation; Prosocial; and, Employment/Occupation) are combined and developed into a mean score. These scores range from 0-32.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread=".37"/>
                    <measurement group_id="O2" value="10.32" spread=".39"/>
                    <measurement group_id="O3" value="10.82" spread=".36"/>
                    <measurement group_id="O4" value="9.02" spread=".38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atomox/CR</title>
          <description>Patients are given the drug Atomoxetine and Cognitive Remediation training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="E2">
          <title>Atomox/Control</title>
          <description>Patients are given the drug Atomoxetine and Remediation Control training.&#xD;
Atomoxetine: 40mg 2po qam</description>
        </group>
        <group group_id="E3">
          <title>Placebo/CR</title>
          <description>Patients are given a Placebo and Cognitive Remediation training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Control</title>
          <description>Patients are given Placebo and Remediation Control training.&#xD;
Placebo: 40mg 2po qam</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carol A. Tamminga, MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-645-2789</phone>
      <email>carol.tamminga@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

